134 related articles for article (PubMed ID: 7511934)
1. CD 34 immunotyping of blasts in myelodysplasia.
Oertel J; Oertel B; Beyer J; Huhn D
Ann Hematol; 1994 Feb; 68(2):77-80. PubMed ID: 7511934
[TBL] [Abstract][Full Text] [Related]
2. Immunotyping of blasts in refractory anaemia with excess of blasts.
Oertel J; Kleiner S; Huhn D
Br J Haematol; 1993 Jun; 84(2):305-9. PubMed ID: 7691147
[TBL] [Abstract][Full Text] [Related]
3. CD34 immunophenotyping of blasts in myelodysplasia.
Oertel J; Huhn D
Leuk Lymphoma; 1994 Sep; 15(1-2):65-9. PubMed ID: 7532058
[TBL] [Abstract][Full Text] [Related]
4. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
5. CD34 immunohistochemical staining of bone marrow biopsies in myelodysplastic syndromes.
Min YH; Lee ST; Min DW; Kim TS; Lee CH; Lee BK; Hahn JS; Ko YW
Yonsei Med J; 1995 Mar; 36(1):1-8. PubMed ID: 7537931
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
7. Immunotyping of blasts in human bone marrow.
Oertel J; Oertel B; Schleicher J; Huhn D
Ann Hematol; 1996 Mar; 72(3):125-9. PubMed ID: 8766253
[TBL] [Abstract][Full Text] [Related]
8. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
[TBL] [Abstract][Full Text] [Related]
9. Characterization of clonogenic cells in refractory anemia with excess of blasts (RAEB-CFU): response to recombinant hematopoietic growth factors and maturation phenotypes.
Schouten HC; Delwel R; Bot FJ; Hagemeijer A; Touw IP; Löwenberg B
Leuk Res; 1989; 13(3):245-51. PubMed ID: 2785235
[TBL] [Abstract][Full Text] [Related]
10. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.
Soligo D; Delia D; Oriani A; Cattoretti G; Orazi A; Bertolli V; Quirici N; Deliliers GL
Leukemia; 1991 Dec; 5(12):1026-30. PubMed ID: 1723130
[TBL] [Abstract][Full Text] [Related]
11. Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score.
Oscier DG; Worsley A; Darlow S; Figes A; Williams JD; Hamblin TJ
Leuk Res; 1989; 13(9):833-9. PubMed ID: 2796388
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms accounting for the impaired natural-killer cell activity in refractory anaemia with excess of blasts.
Eliopoulos GD; Coulocheri SA; Eliopoulos AG; Katrinakis G; Karkavitsas N; Kyriakou D; Vaiopoulos G; Foudoulakis A
Eur J Haematol; 1992 May; 48(5):237-43. PubMed ID: 1379537
[TBL] [Abstract][Full Text] [Related]
13. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes.
Baur AS; Meugé-Moraw C; Schmidt PM; Parlier V; Jotterand M; Delacrétaz F
Eur J Haematol; 2000 Feb; 64(2):71-9. PubMed ID: 10997326
[TBL] [Abstract][Full Text] [Related]
14. QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens.
Horny HP; Wehrmann M; Schlicker HU; Eichstaedt A; Clemens MR; Kaiserling E
J Clin Pathol; 1995 Apr; 48(4):291-4. PubMed ID: 7542289
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
16. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
17. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology.
Orazi A; Chiu R; O'Malley DP; Czader M; Allen SL; An C; Vance GH
Mod Pathol; 2006 Dec; 19(12):1536-45. PubMed ID: 17041567
[TBL] [Abstract][Full Text] [Related]
19. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
20. Circulating micromegakaryocytes in myelodysplasia.
Erber WN; Jacobs A; Oscier DG; O'Hea AM; Mason DY
J Clin Pathol; 1987 Nov; 40(11):1349-52. PubMed ID: 3320097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
